Johan Lund is currently Head of Myeloma Section at Karolinska University Hospital’s hematology department. He received his medical degree from University of Gothenburg and his PhD in hematology from Karolinska Institutet.
Ola Landgren serves as Professor of Medicine and Chief of Myeloma Program and Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center at University of Miami. Previously, Dr. Landgren served as Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York City; and prior to that, he was the Chief of the Myeloma Section at the National Cancer Institute at the National Institutes of Health in Bethesda, Maryland. Dr. Landgren received his M.D. and Ph.D. from Karolinska Institutet in Stockholm, Sweden.
Fredrik Schjesvold is Head of Oslo Myeloma Center, in Oslo, Norway, head of the Norwegian myeloma association, president of the Nordic Myeloma Study Group and a member of the European Myeloma Network board. He is national investigator of 36 clinical trials in multiple myeloma and principal investigator for four academic studies. He is a co-author of ESMO and IMWG guidelines, as well as lead author of the Norwegian myeloma guidelines.
Dr. Gunilla Enblad is Professor of oncology, Uppsala University, since 2013 and senior consultant, Uppsala University hospital. She has worked as oncologist in training and specialist at the Department of Oncology, Uppsala University Hospital since 1988. Her areas of research include clinical and tumor biological studies of malignant lymphomas, as well as immunotherapy including clinical studies of CAR T cells. She is the author of more than 170 scientific publications, review articles and book chapters. Since 2019, she is Chairman of the Swedish CAR T-cell group and sits on the boards of the Swedish cancer society (Cancerfonden) and the Department of Immunology, Genetics and Pathology, Uppsala University. Since 2017, she is also a Member of the Royal Society of Sciences, Uppsala.
Dr. Rizwan Romee is an Associate Professor of Medicine at Harvard Medical School and director of the haploidentical donor transplant program at Dana Farber Cancer Institute (DFCI), Boston. He is also the principal investigator of the Romee Lab for NK Cell Gene Manipulation and Therapy at DFCI. The research focus of his laboratory is genetic manipulation of the human Natural Killer (NK) cells to enhance their anti-tumor function and simultaneously modulate the highly immune suppressive tumor microenvironment (TME). He is currently leading the translational NK cell program at DF/Harvard Cancer Center evaluating memory-like NK cells in combination with novel immune-modulatory agents in patients with advanced malignancies including AML and MDS relapsed after stem cell transplantation, MRD+ multiple myeloma (in combination with CD38 ARM) and head and neck cancer (in combination with CTLA-4 blockade/ipilimumab and IL-15 super-agonist).